EBITDA

AI finance firm Terzo hires a partnership expert to expand its platform that turns enterprise contracts into billions of dollars in recovered profit.

A coalition of utilities seeks to suspend competitive bidding on grid projects, a move critics say is a power grab that will cost consumers billions.

The digital bank is rolling out a suite of new investment funds, including a multi-asset portfolio and a physical gold fund, for retail investors.

Fresh off a stellar quarter, Everus Construction Group heads to key conferences to detail its role in powering data centers and America's energy transition.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Following a record year of profit and growth, the French diagnostics firm secures a major analyst endorsement, signaling a powerful turnaround. What's next?

With revenue hitting a record $47.6M, TerraCycle proves sustainability is profitable. But as it raises millions, can it overcome greenwashing critiques?

A new forensic audit claims the global economy is designed to extract value and will hit a structural breaking point by 2030. Is it a system failure?

Dubai-based robotics firm Micropolis AI is under scrutiny after a delayed annual report triggered a warning from the NYSE American exchange.

Newly independent, auto supplier Versigent will meet investors to prove its critical role in powering the EV and autonomous vehicle revolution.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

With M&A veteran Jay Wright taking control, Worldwide NFT is ditching its namesake focus for an aggressive acquisition strategy in AI, robotics, and software.

New research on the gut-brain axis and smarter antibiotic use is transforming veterinary medicine, moving from theory to practice for healthier pets.

A bold proposal urges Ottawa to treat childcare and elder care like pipelines, reframing social support as critical economic infrastructure.

Newly public Yesway faces its first major test with its Q1 earnings. Investors will scrutinize if its aggressive expansion can meet high analyst expectations.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

The coatings giant secured John Deere's highest supplier rating and was named Supplier of the Year, signaling deep strategic partnership and market leadership.

A pivotal Q4 sees Exicom's consolidated business break even for the first time since its Tritium acquisition, driven by a global turnaround and Indian EV dominance.

An upcoming Singapore conference reveals how litigation finance is becoming a multi-billion dollar asset class, with Asia as its new, rapidly expanding frontier.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.